<DOC>
	<DOC>NCT02161952</DOC>
	<brief_summary>The aim of this study was to assess whether two-year treatment with Pirfenidone influence necro-inflammation, fibrosis and steatosis in patients with chronic hepatitis C.</brief_summary>
	<brief_title>Pirfenidone, an Antifibrotic and Antiinflammatory Drug</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Pirfenidone</mesh_term>
	<mesh_term>Anti-Inflammatory Agents</mesh_term>
	<criteria>Patients with established advanced liver disease caused by hepatitis C virus (HCV) chronic infection defined by a positive test for antiHCV antibodies and detectable serum HCV RNA (Amplicor HCV 2.0 polymerase chain reaction (PCR) assay). Sign an informed consent form to allow the collection of liver biopsies before and after treatment. No antifibrotic, antiviral or immunosuppressive drugs for at least 6 months before starting pirfenidone therapy. No alcohol intake for at least 6 months before nor during Pirfenidone (PFD) treatment. Patients with clinical contraindications to hepatic biopsy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Fibrosis, necroinflammation, hepatitis C chronic</keyword>
</DOC>